Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …

In the past 15 years, B cells have been rediscovered to be not merely bystanders but rather
active participants in autoimmune aetiology. This has been fuelled in part by the clinical …

Antibodies and antibody-derived macromolecules have established themselves as the
mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure …

Increasing evidence indicates the involvement of B cells in the pathogenesis of multiple
sclerosis (MS), but their precise roles are unclear. In this Review, we provide an overview of …

Therapeutic monoclonal antibodies are among the most effective biotherapeutics to date. An
important aspect of antibodies is their ability to bind antigen while at the same time recruit …

Abstract Disease Overview Chronic lymphocytic leukemia (CLL) is the commonest leukemia
in western countries. The disease typically occurs in elderly patients and has a highly …

For 20 years, monoclonal antibodies (mAbs) have been a standard component of cancer
therapy, but there is still much room for improvement. Efforts continue to build better cancer …

Complement activation by antibodies bound to pathogens, tumors, and self antigens is a
critical feature of natural immune defense, a number of disease processes, and …

Chimeric antigen receptor T (CAR-T) cell therapy has produced impressive results in clinical
trials for B-cell malignancies. However, safety concerns related to the inability to control CAR …

Preclinical strategies that are used to identify potential drug candidates include target-based
screening, phenotypic screening, modification of natural substances and biologic-based …